Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027997 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
A Phase 2 study, sponsored by Addex Pharma S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05027997 is a Phase 2 study that has completed, run by Addex Pharma S.A.. The registered enrollment target is 15 participants.
The verdict
NCT05027997, a Phase 2 study, has completed, sponsored by Addex Pharma S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.
Interventions
- DRUG Placebo
- DRUG Dipraglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2022-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027997
The ClinicalTrials.gov registry entry for NCT05027997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addex Pharma S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05027997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05027997 about?
NCT05027997 is a clinical study titled "Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm". This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency ...
What is the current status of trial NCT05027997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-10-06. Estimated completion is 2022-11-27.
What interventions are being tested in trial NCT05027997?
The interventions under investigation include: Placebo (DRUG), Dipraglurant (DRUG).
Who is sponsoring clinical trial NCT05027997?
This trial is sponsored by Addex Pharma S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.